pemetrexed / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

180 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemetrexed / Generic mfg.
MK-2870-009, NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Recruiting
3
520
US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pemetrexed, Carboplatin, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
09/28
06/30
COMPEL, NCT04765059: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
98
Europe, US, RoW
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
AstraZeneca, Parexel
Non-small Cell Lung Cancer
12/24
12/24
NCT06452277: A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Not yet recruiting
3
278
Europe, Canada, Japan, US, RoW
BAY2927088, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Bayer
Advanced Non-small Cell Lung Cancer, HER2 Mutation
06/26
05/28
NeoADAURA, NCT04351555 / 2020-000058-89: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Data from NeoADAURA trial for EGFRm NSCLC
Recruiting
3
328
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291; TAGRISSO, Cisplatin, Carboplatin, Placebo, Pemetrexed
AstraZeneca
Non-Small Cell Lung Cancer
07/24
06/29
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
04/25
QUILT2023, NCT03520686: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Active, not recruiting
3
1538
US
N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, Pembrolizumab, Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
ImmunityBio, Inc.
Non Small Cell Lung Cancer
10/25
04/26
NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Not yet recruiting
3
686
NA
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
JAB-21822 3002, NCT06416410: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Not yet recruiting
3
392
NA
JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin
Jacobio Pharmaceuticals Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
09/26
02/27
BGB-A317-290-LTE1, NCT04164199 / 2019-002554-23: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation
3
300
RoW
Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
BeiGene
Advanced Malignancies
12/26
12/26
NCT06430437: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Not yet recruiting
3
300
RoW
SHR-A1811, Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer With HER2- Mutations
02/26
04/27
TROPION Lung15, NCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruiting
3
630
NA
Dato-DXd, DS-1062a, Osimertinib, Tagrisso, AZD9291, Pemetrexed, Carboplatin, Cisplatin
AstraZeneca, Daiichi Sankyo
Metastatic Non-small Cell Lung Cancer
09/26
02/28
KEYLYNK-006, NCT03976323 / 2018-004720-11: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, )

Calendar Jul 2024 - Sep 2024: From KEYLYNK-006 trial +/- Lynparza for 1L metastatic non squamous NSCLC
Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, PLATINOL®-AQ, Olaparib, LYNPARZA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Carcinoma, Non-squamous Non-small-cell Lung
02/24
01/25
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Not yet recruiting
3
676
NA
BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi
Bio-Thera Solutions
Carcinoma, Non-Small-Cell Lung
07/27
10/28
CheckMate 227, NCT02477826 / 2014-003630-23: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Checkmark Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Checkmark From CheckMate 227 trial in combination with Yervoy for NSCLC at ASCO 2021
More
Active, not recruiting
3
2748
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non-Small Cell Lung Cancer
08/24
08/24
IMpower010, NCT02486718 / 2014-003205-15: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer []

Checkmark Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Aug 2022 - Aug 2022: Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Checkmark Data from IMpower010 trial for stage IB-IIIA NSCLC
Aug 2022 - Aug 2022: Data from IMpower010 trial for stage IB-IIIA NSCLC
Checkmark Approval for adjuvant NSCLC based on IMpower010
More
Active, not recruiting
3
1280
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A; TECENTRIQ, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Hoffmann-La Roche
Non-Small Cell Lung Cancer
01/24
08/35
NCT04736173: Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
3
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
08/24
07/27
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Recruiting
3
250
RoW
Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
09/24
11/24
MK-3475A-D77, NCT05722015: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
378
Europe, Japan, US, RoW
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
MILES-4, NCT01656551 / 2012-000164-25: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Active, not recruiting
3
232
Europe
Gemcitabine, Pemetrexed, Cisplatin
National Cancer Institute, Naples
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
11/24
11/24
AcceleRET Lung, NCT04222972: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
223
Europe, Japan, US, RoW
Pralsetinib, BLU-667, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab, Gemcitabine, Paclitaxel, Nab-Paclitaxel
Hoffmann-La Roche
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue
06/25
06/25
NCT01993810: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting
3
330
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
12/24
10/25
ADVANCE, ChiCTR2000040590: Almonertinib Plus Radiotherapy compared with Concurrent RadioChemotherapy in the treatment of unresectable EGFR-mutated stage III Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Not yet recruiting
3
254
 
Almonertinib 110mg PO once daily ;Cisplatin（75mg/m2），and 500 milligrams per square meter (mg/m2) Pemetrexed
Cancer Hospital Chinese Acadmey of Medical Sciences, Shenzhen Center; Shanghai chest hospital, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
SPBPDC, NCT05648071: First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial

Recruiting
3
60
RoW
Sintilimab, Bevacizumab, Pemetrexed, Nedaplatin
Qianfoshan Hospital
Advanced Non-squamous Non-Small-Cell Lung Cancer
12/24
07/25
ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting
3
1210
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation, Inspection, Visual Inspection, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
12/24
12/24
NCT05132413: A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Not yet recruiting
3
561
NA
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab, Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin, Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
12/24
12/24
HS-10241-301, NCT06110663: A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Not yet recruiting
3
314
NA
HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
12/24
02/25
HARMONi, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Recruiting
3
470
Europe, Canada, US, RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
01/25
01/26
DESTINY-Lung04, NCT05048797 / 2021-000634-33: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Lung04 trial for locally advanced/metastatic NSCLC
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for advanced NSCLC (based on DESTINY-Lung04 trial)
Checkmark Initiated DESTINY-Lung04 trial in HER2 exon 19/20 gene mutation-positive advanced or metastatic NSCLC
Oct 2021 - Oct 2021: Initiated DESTINY-Lung04 trial in HER2 exon 19/20 gene mutation-positive advanced or metastatic NSCLC
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Trastuzumab Deruxtecan, DS-8201a; T-DXd, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/25
03/27
IMpower030, NCT03456063 / 2017-002857-12: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data from IMpower030 trial for neoadjuvant NSCLC
Hourglass Jan 2022 - Dec 2022 : EFS data from P3 IMpower030 trial for resectable stage II, IIIA, or select IIIB NSCLC
Active, not recruiting
3
453
Europe, Japan, US, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Tecentriq, Placebo Comparator, Nab-paclitaxel, Abraxane, Pemetrexed, Alimta, Carboplatin, Cisplatin, Gemcitabine, Gemzar
Hoffmann-La Roche
Non-Small-Cell Lung
01/25
01/25
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
SKB264-Ⅲ-09, NCT05870319: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Recruiting
3
356
RoW
SKB264, Pemetrexed, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/25
09/26
SAFFRON, NCT05261399: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting
3
324
Europe, Canada, Japan, US, RoW
Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
06/25
12/26
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
453
RoW
Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin
BeiGene
Non Small Cell Lung Cancer
06/25
11/25
NRG LU-006, NCT04158141: Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Terminated
3
16
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Decortication, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Pemetrexed, MTA, Multitargeted Antifolate, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Pencil Beam Scanning, Pleurectomy, Excision of Pleura, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
NRG Oncology, National Cancer Institute (NCI)
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
11/23
11/23
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting
3
642
RoW
AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel
Akeso
Locally Advanced or Metastatic NSCLC
08/25
11/26
MRG002-010, NCT05754853: A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting
3
290
RoW
MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injection
Shanghai Miracogen Inc.
Advanced or Metastatic Urothelium Cancer
10/25
01/27
KEYVIBE 007, NCT05226598 / 2021-004564-94: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Active, not recruiting
3
700
Europe, Japan, US, RoW
Pembrolizumab/Vibostolimab, MK-7684A, Carboplatin, PARAPLATIN®, Paraplatin NovaPlus ®, Cisplatin, Platinol-AQ®, Paclitaxel, TAXOL®, ONXOL®, Nab-paclitaxel, ABRAXANE®, Pemetrexed, Alimta®, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC
Metastatic Non-Small Cell Lung Cancer
06/26
09/27
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
62
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
NCT05112965: An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Recruiting
3
100
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Pemetrexed, Paclitaxel, Enzalutamide, Xtandi
Hoffmann-La Roche
Neoplasms
12/25
12/25
EXCLAIM-2, NCT04129502 / 2019-001845-42: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Active, not recruiting
3
354
Europe, Canada, Japan, US, RoW
TAK-788, AP32788, Mobocertinib, Pemetrexed, Alimta, Cisplatin, Carboplatin
Takeda
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
DZD9008, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
APEX, NCT04762459: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Enrolling by invitation
3
606
RoW
Almonertinib, Pemetrexed, Cisplatin
Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Carcinoma
05/26
05/29
NCT06096844: Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting
3
304
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
06/26
06/26
KEYLYNK-012, NCT04380636 / 2019-003237-41: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/)

Calendar Jan 2026 - Dec 2026: Data from KEYLINK-012 trial in combination with Lynparza for stage III NSCLC
Active, not recruiting
3
870
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Placebo for olaparib, Etoposide, VEPESID®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, Paclitaxel, TAXOL®, Pemetrexed, ALIMTA®, Thoracic Radiotherapy, Durvalumab, IMFINZI®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
07/26
02/27
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LungMate-008, NCT04772287: Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC

Not yet recruiting
3
341
NA
Toripalimab, Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel, Toripalimab mimetic (placebo)
Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
12/26
12/27
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
NCT05047250: A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Recruiting
3
60
RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Non-Small Cell Lung Cancer
02/27
08/27
MK-2870-004, NCT06074588: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Recruiting
3
556
Canada, US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Docetaxel, TAXOTERE®, Pemetrexed, ALIMTA®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
05/27
03/30
AVANZAR, NCT05687266 / 2021-004606-21: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, MEDI4736, Imfinzi, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
AstraZeneca, AstraZeneca AB
NSCLC
02/27
02/27
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
975
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, Keytruda, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
STAR-121, NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Recruiting
3
720
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
AdvanTIG-306, NCT05791097: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Withdrawn
3
980
NA
Ociperlimab, WCD118, Placebo, Tislelizumab, VDT482, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
12/27
12/27
M22-142, NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn
3
250
NA
Telisotuzumab Vedotin, ABBV-399, Osimertinib, Cisplatin, Carboplatin, Pemetrexed
AbbVie
Non-Small Cell Lung Cancer
04/28
04/28
eVOLVE-Lung02, NCT05984277: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
AstraZeneca
Metastatic Non-small Cell Lung Cancer
05/28
05/29
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
KEYVIBE-006, NCT05298423: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/)

Recruiting
3
784
Europe, Japan, US, RoW
pembrolizumab/vibostolimab, MK-7684A, durvalumab, IMFINZI®, cisplatin, PLATINOL-AQ®, pemetrexed, ALIMTA®, etoposide, TOPOSAR®, carboplatin, PARAPLATIN®, paclitaxel, TAXOL®, thoracic radiotherapy
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/28
09/29
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Not yet recruiting
3
632
NA
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
10/28
10/31
EA5163, NCT03793179: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active, not recruiting
3
600
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/28
12/28
EA5181, NCT04092283: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active, not recruiting
3
660
US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/28
12/28
Pulse, NCT05692999: Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Recruiting
3
1166
Europe
Pembrolizumab 200 mg Q6W, Pemetrexed 500 mg/m^2 Q3W, Pembrolizumab 200 mg Q3W or 400 mg Q6W
Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Non-squamous Lung Cancer
01/29
01/29
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
280
US
Durvalumab, Tremelimumab, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
NRG-LU008, NCT05624996: Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Recruiting
3
474
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
10/31
10/36
2007-002574-63: Essai randomisé de phase 2-3 testant l’association Pemetrexed-Cisplatine avec ou sans bevacizumab à 15 mg/kg, dans le mésothéliome malin de la plèvre (MPM).

Ongoing
2/3
445
Europe
AVASTIN, AVASTIN, AVASTIN
CHU de Caen
pleural mesothelioma malignant
 
 
2021-006044-27: Trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of treatment by chemotherapy plus pembrolizumab in patients with advanced Lung Cancer

Ongoing
2/3
1360
Europe
Powder for concentrate for solution for infusion, Solution for infusion, , Powder for solution for infusion, Solution for solution for infusion
IFCT, IFCT
Advanced Non Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting
2/3
700
RoW
HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin
Taizhou Hanzhong biomedical co. LTD
Nonsquamous Non-small Cell Lung Cancer
09/22
09/23
NCT02784171 / 2016-002286-60: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Active, not recruiting
2/3
520
Europe, Canada
Cisplatin, Pemetrexed, Pembrolizumab
Canadian Cancer Trials Group, National Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique
Mesothelioma
04/23
06/24
ACTPI, NCT03380468: Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Recruiting
2/3
300
RoW
cisplatin plus pemetrexed
Fudan University
Lung Neoplasms
01/24
12/25
NCT05209256: Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Not yet recruiting
2/3
90
NA
Chemotherapy, pemetrexed, Pulaile, Alflutinib plus chemotherapy, AST2818
The First Affiliated Hospital of Henan University of Science and Technology
NSCLC
01/24
01/25
NCT06335355: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Not yet recruiting
2/3
401
RoW
Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
Shanghai Shengdi Pharmaceutical Co., Ltd
Non-squamous Non-small Cell Lung Cancer
10/28
10/30
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
840
Japan, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
AbbVie
Non-Small Cell Lung Cancer
10/31
10/31
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, GDC-6036, RO7435846, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
06/24
06/29
NCT05756972: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2/3
374
RoW
PM8002, Placebo, Carboplatin, Pemetrexed
Biotheus Inc.
NSCLC
03/25
12/25
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
SKYSCRAPER-06, NCT04619797 / 2020-002851-39: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-06 trial in combination with Tecentriq for advanced non squamous NSCLC
Active, not recruiting
2/3
542
Europe, Canada, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
05/27
05/27
NCT04929041: Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Recruiting
2/3
427
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/27
12/27
KRYSTAL-7, NCT04613596 / 2020-003101-58: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Hourglass Jul 2023 - Dec 2023 : Data from KRYSTAL-7 trial in combination with pembrolizumab for advanced NSCLC
Checkmark Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Recruiting
2/3
806
Europe, Canada, US, RoW
Adagrasib, Pembrolizumab, Pemrolizumab
Mirati Therapeutics Inc.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
10/28
10/29
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
 

Download Options